Business
EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion
EQT Life Sciences, a leading European life sciences venture capital firm, is pleased to share that CSL has entered into a strategic collaboration with its portfolio company VarmX to support the development of its lead asset, VMX-C001. CSL has also entered into an exclusive option agreement with VarmX shareholders to acquire all issued and outstanding shares of the company in a transaction worth up to USD 2.2 billion.
About this update from Eqt Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"VarmX is developing a bypass agent to restore coagulation for patients facing life-threatening bleeding or requiring emergency surgery while on anticoagulants that target Factor Xa","length":180,"tagName":"p"}]},{"val":[{"type":"text","content":"Under the agreement, CSL will fully fund clinical development of VMX-C001 and pay VarmX shareholders USD 117 million upfront for an exclusive option to acquire VarmX, in a transaction worth up to USD 2.2 billion","length":211,"tagName":"p"}]},{"val":[{"type":"text","content":"EQT Life Sciences has backed VarmX since 2020, actively supporting the Company at board level as it successfully completed a first-in-human clinical study and obtained FDA clearance to start a global registrational Phase 3 trial","length":228,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":619,"olType":false},{"type":"text","content":"STOCKHOLM, Sept. 16, 2025 /PRNewswire/ -- EQT Life Sciences, a leading European life sciences venture capital firm, is pleased to share that CSL has entered into a strategic collaboration with its portfolio company VarmX to support the development of its lead asset, VMX-C001. CSL has also entered into an exclusive option agreement with VarmX shareholders to acquire all issued and outstanding shares of the company in a transaction worth up to USD 2.2 billion.","length":462,"tagName":"p"},{"type":"text","content":"VarmX, based in Leiden, the Netherlands, is a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated Factor Xa (FXa DOACs) and inherited coagulation disorders. More than 20 million patients globally take FXa inhibitors as chronic anticoagulation therapy, with approximately 3 per cent of these patients experiencing severe bleeding or requiring urgent surgery. Despite the unmet clinical need, no fully approved therapeutic agent is currently available in the E.U. or the U.S. for treating acute major bleeding in patients on Factor Xa inhibitors.","length":606,"tagName":"p"},{"type":"text","content":"VMX-C001 is an investigational product, designed to bypass the FXa anticoagulation activity and swiftly restore coagulation in patients in urgent surgery and severe bleeding situations. Under the terms of the strategic collaboration agreement, CSL will fully fund VarmX's global P...